919.865.2827
dporper@wyrick.com
Bio
Dan advises technology and life sciences companies, healthcare investors, and research institutions on complex commercial transactions involving intellectual property, technology, artificial intelligence, data, and innovative financing structures. From emerging growth companies to multinational enterprises, clients rely on Dan to structure strategic business relationships, maximize the value of their intellectual property, and help bring new products and technologies to market.
Dan guides clients through the full lifecycle of innovation, from early-stage research and technology transfer to global partnering, manufacturing, financing, commercialization, and corporate transactions. Known for his practical, business-oriented approach, he helps clients navigate complex negotiations by balancing legal risk with commercial objectives. His work spans the biotechnology, pharmaceutical, diagnostics, medical device, digital health, clinical research, artificial intelligence, software, and broader technology sectors.
Dan regularly serves as counsel on clients’ most significant collaborations, licensing transactions, companion diagnostic partnerships, and other complex commercial arrangements involving intellectual property, technology, and data. He also represents healthcare investors and life sciences companies in royalty monetizations, revenue interest financings, non-dilutive product financings, and other innovative capital structures supporting the development and commercialization of biopharmaceutical products.
Dan also advises on the technology, intellectual property, and related commercial aspects of mergers and acquisitions, venture financings, strategic investments, and spin-outs, working closely with the firm’s corporate attorneys.
Dan earned his B.A. from the University of South Florida and his J.D. from Syracuse University College of Law.
- Listed as Best Lawyers “Lawyer of the Year” – Technology Law (2022)
- Listed among The Best Lawyers in America: Technology Law (2021-2026); Biotechnology and Life Sciences Practice (2026)
- Listed among Business North Carolina Magazine Legal Elite: Intellectual Property (2025-2026)
- American Bar Association
- North Carolina Bar Association
- North Carolina State Bar
- Licensing Executives Society
- Represented global pharmaceutical company in a collaboration involving the generation of antibodies and the licensing of associated intellectual property
- Represented investor in $100,000,000 pharmaceutical product financing transaction
- Represented bank in the negotiation of agreements for the in-licensing of critical technology infrastructure provided to it on a SaaS basis
- Represented diagnostic company in a collaboration with a large diagnostic company involving the development and commercialization of diagnostics
- Represented pharmaceutical company in cross-border collaboration involving the licensing of its product to a development and commercialization partner in China;
- Represented digital therapeutics company in a development and commercialization transaction to develop a digital therapeutic for depression;
- Represented pharmaceutical company in collaboration with European partner for the development and commercialization of its product in Europe
- Represented investor in $70,000,000 pharmaceutical product financing transaction
- Represented numerous companies in the licensing of technologies from universities
